Pyrrolidine derivatives as prostaglandin modulators

Details Pyrrolidine derivatives as prostaglandin modulators Pyrrolidine derivatives as prostaglandin modulators

2009-08-03

2011-11-15

Anderson, Rebecca (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S556000

Reexamination Certificate

active

08058305

ABSTRACT:
Substituted pyrrolidine compounds are provided, and methods of treatment and pharmaceutical composition that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteoporosis and other destructive bone disease or disorder, and other diseases and disorders associated with the prostaglandin family of compounds. In a preferred aspect, a substituted pyrrolidine compound is administered to a subject in coordination with a phosphodiesterase inhibitor compound.

REFERENCES:
patent: 3873566 (1975-03-01), Scribner
patent: 3976660 (1976-08-01), Ondetti et al.
patent: 4003911 (1977-01-01), Scribner
patent: 4033989 (1977-07-01), Bundy
patent: 4090019 (1978-05-01), Williams et al.
patent: 4211876 (1980-07-01), Scribner
patent: 4753945 (1988-06-01), Gilbard et al.
patent: 5010086 (1991-04-01), Lesher et al.
patent: 5091431 (1992-02-01), Tulshian et al.
patent: 5605814 (1997-02-01), Abramovitz et al.
patent: 5759789 (1998-06-01), Abramovitz et al.
patent: 5981527 (1999-11-01), Daugan et al.
patent: 6001847 (1999-12-01), Daugan et al.
patent: 6006735 (1999-12-01), Schlough et al.
patent: 6040309 (2000-03-01), Dack et al.
patent: 6043252 (2000-03-01), Bombrun
patent: 6054475 (2000-04-01), Martin et al.
patent: 6100270 (2000-08-01), Campbell
patent: 6117881 (2000-09-01), Bombrun
patent: 6121279 (2000-09-01), Gutterer
patent: 6127363 (2000-10-01), Doherty, Jr. et al.
patent: 6140329 (2000-10-01), Daugan
patent: 6143746 (2000-11-01), Daugan et al.
patent: 6143757 (2000-11-01), Daugan et al.
patent: 6156753 (2000-12-01), Doherty, Jr. et al.
patent: 6207829 (2001-03-01), Dunn et al.
patent: 6211197 (2001-04-01), Belley et al.
patent: 6288120 (2001-09-01), Cameron et al.
patent: 6900336 (2005-05-01), Elworthy et al.
patent: 7635713 (2009-12-01), Liao et al.
patent: 2003/0120079 (2003-06-01), Elworthy et al.
patent: 25 27 989 (1977-01-01), None
patent: 463 756 (1992-01-01), None
patent: 752 421 (1997-01-01), None
patent: 93/06104 (1993-04-01), None
patent: 93/07149 (1993-04-01), None
patent: 93/12095 (1993-06-01), None
patent: 94/00453 (1994-01-01), None
patent: 94/05661 (1994-03-01), None
patent: 96/03380 (1996-02-01), None
patent: 96/06822 (1996-03-01), None
patent: 97/00863 (1997-01-01), None
patent: 97/00864 (1997-01-01), None
patent: 01/46140 (2001-06-01), None
R.M. Scribner, “Azaprostanoids I, Synthesis of (RAC)-11-Desoxy-12-Azaprostanoids”, Tetrahedron Letters, No. 43, pp. 3853-3856, XP002260529 (1976).
A.D. Cale, Jr., et al., “A series of central nervous system stimulants based on the 4-substituted 3, 3-diphenyl-2-pyrrolidinone skeleton. II”, Journal of Medicinal Chemistry, vol. 10, No. 2, pp. 214-222 (1967).
M. Tandon, et al., “Substrate specificity of human prolyl-4-hydroxylase”, Bioorganic & Medicinal Chemistry Letters, vol. 8, No. 10, pp. 1139-1144 (1998).
G.B. Bennett, et al., Journal of Medicinal Chemistry, vol. 19, No. 5, pp. 715-719 (1976).
A. Ichikawa, et al., Journal of Lipid Mediators and Cell Signaling, vol. 14, pp. 83-87 (1996).
T. Minami, et al., The British Journal of Pharmacology, vol. 112, pp. 735-740 (1994).
S.J.F. MacDonald, et al., Journal of Medicinal Chemistry, vol. 41, No. 21, pp. 3919-3922 (Oct. 8, 1998).
J. Cooper, et al., J. Chem. Soc. Perkin Trans., vol. pp. 1313-1317 (1993).
R.A. Coleman, et al., “Prostanoids and their Receptors”, Comprehensive Medicinal Chemistry, vol. 3, pp. 643-714 (1990).
R.A. Coleman, et al., Pharmaological Reviews, vol. 46, No. 2, pp. 205-229 (1994).
F. Ushikubi, et al., JPN. J. Pharmacol., vol. 83, pp. 279-285 (2000).
P.J. Gardiner, BR. J. Pharmac., vol. 87, pp. 45-56 (1986).

Affiliated with

Also associated with

Rating

Pyrrolidine derivatives as prostaglandin modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrrolidine derivatives as prostaglandin modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolidine derivatives as prostaglandin modulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4272221